Related Experiment Videos
[Congenital enzymopenic methemoglobinemia and its pharmacogenetic aspects]
Bilten Za Hematologiju I Transfuziju
|January 1, 1977
Insights
Hereditary enzymopenic methemoglobinemia requires long-term monitoring. Patients and carriers remained healthy, with no dangerous methemoglobin levels observed over ten years.
Area of Science:
- Genetics
- Hematology
- Biochemistry
Background:
- Hereditary enzymopenic methemoglobinemia is a rare genetic disorder affecting hemoglobin function.
- Long-term follow-up studies are crucial for understanding the clinical course and management of such conditions.
Observation:
- This study followed four families with hereditary enzymopenic methemoglobinemia for nearly a decade.
- Patients and gene carriers were monitored for methemoglobin levels and overall health.
Findings:
- No dangerous elevations in methemoglobin levels were observed in patients throughout the 10-year follow-up.
- Gene carriers were asymptomatic, indicating a generally benign carrier state.
- One family reported neonatal deaths due to convulsions, highlighting potential severe outcomes in some cases.
- No instances of mental retardation were noted in the studied families.
Implications:
- Proactive patient and physician education may prevent dangerous methemoglobin level exacerbations.
- Understanding the genetic transmission and clinical variability is key for genetic counseling.
- Further research into the specific enzyme deficiencies and their long-term impact is warranted.
Abstract:
The authors report on their experience in nearly 10 years follow-up of four families with hereditary enzymopenic methemoglobinemia. In patients a dangerous elevation of methemoglobin level was never observed, what is probably due to the information of the patients and the family doctor about the nature of the patient's constitution. All gene--carriers were practically healthy. In one family 10 children died from convulsions as newborns. Mental retardation was not present in these four families.